{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:49:53Z","timestamp":1791416993683,"version":"4.3.3"},"reference-count":247,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Microbiol"],"DOI":"10.1038\/s41579-026-01372-1","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T10:33:35Z","timestamp":1791369215000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Towards broader-spectrum direct-acting antivirals against RNA viruses"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5785-8276","authenticated-orcid":false,"given":"Hendrik Jan","family":"Thibaut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9265-6028","authenticated-orcid":false,"given":"Dirk","family":"Jochmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Van Dijck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5708-1321","authenticated-orcid":false,"given":"Manon","family":"Laporte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5616-8548","authenticated-orcid":false,"given":"Laurens","family":"Liesenborghs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Neyts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"1372_CR1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","volume":"21","author":"AJ Pollard","year":"2021","unstructured":"Pollard, A. J. & Bijker, E. M. A guide to vaccinology: from basic principles to new developments. Nat. Rev. Immunol. 21, 83\u2013100 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"1372_CR2","doi-asserted-by":"publisher","first-page":"e1172","DOI":"10.1016\/S2214-109X(21)00205-9","volume":"9","author":"K Chumakov","year":"2021","unstructured":"Chumakov, K., Ehrenfeld, E., Agol, V. I. & Wimmer, E. Polio eradication at the crossroads. Lancet Glob. Health 9, e1172\u2013e1175 (2021).","journal-title":"Lancet Glob. Health"},{"key":"1372_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-025-01242-6","volume":"10","author":"J Pattyn","year":"2025","unstructured":"Pattyn, J. et al. Overview of vaccines for adults authorized, recommended, and implemented in the European Union. npj Vaccines 10, 183 (2025).","journal-title":"npj Vaccines"},{"key":"1372_CR4","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/jmv.25593","volume":"92","author":"GA Tannock","year":"2020","unstructured":"Tannock, G. A., Kim, H. & Xue, L. Why are vaccines against many human viral diseases still unavailable; an historic perspective? J. Med. Virol. 92, 129\u2013138 (2020).","journal-title":"J. Med. Virol."},{"key":"1372_CR5","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41577-022-00753-w","volume":"23","author":"BF Haynes","year":"2023","unstructured":"Haynes, B. F. et al. Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies. Nat. Rev. Immunol. 23, 142\u2013158 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"1372_CR6","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S0140-6736(25)00735-4","volume":"406","author":"PS Kulkarni","year":"2025","unstructured":"Kulkarni, P. S. et al. Post-exposure prophylaxis regimen of rabies monoclonal antibody and vaccine in category 3 potential exposure patients: a phase 4, open-label, randomised, active-controlled trial. Lancet 406, 627\u2013635 (2025).","journal-title":"Lancet"},{"key":"1372_CR7","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/S0140-6736(24)01699-4","volume":"404","author":"C Pecenka","year":"2024","unstructured":"Pecenka, C. et al. Respiratory syncytial virus vaccination and immunoprophylaxis: realising the potential for protection of young children. Lancet 404, 1157\u20131170 (2024).","journal-title":"Lancet"},{"key":"1372_CR8","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/s41579-022-00841-7","volume":"21","author":"AM Carabelli","year":"2023","unstructured":"Carabelli, A. M. et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat. Rev. Microbiol. 21, 162\u2013177 (2023).","journal-title":"Nat. Rev. Microbiol."},{"key":"1372_CR9","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/s41564-023-01356-4","volume":"8","author":"SS Toussi","year":"2023","unstructured":"Toussi, S. S., Hammond, J. L., Gerstenberger, B. S. & Anderson, A. S. Therapeutics for COVID-19. Nat. Microbiol. 8, 771\u2013786 (2023).","journal-title":"Nat. Microbiol."},{"key":"1372_CR10","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1093\/cid\/ciaf476","volume":"82","author":"R Draghia-Akli","year":"2026","unstructured":"Draghia-Akli, R. et al. The indispensable value of small-molecule antivirals in epidemic and pandemic preparedness. Clin. Infect. Dis. 82, e49\u2013e55 (2026).","journal-title":"Clin. Infect. Dis."},{"key":"1372_CR11","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.tim.2022.07.002","volume":"30","author":"D Forni","year":"2022","unstructured":"Forni, D., Cagliani, R., Clerici, M. & Sironi, M. Disease-causing human viruses: novelty and legacy. Trends Microbiol. 30, 1232\u20131242 (2022).","journal-title":"Trends Microbiol."},{"key":"1372_CR12","doi-asserted-by":"publisher","DOI":"10.1172\/JCI170236","volume":"133","author":"M Karim","year":"2023","unstructured":"Karim, M., Lo, C.-W. & Einav, S. Preparing for the next viral threat with broad-spectrum antivirals. J. Clin. Invest. 133, e170236 (2023).","journal-title":"J. Clin. Invest."},{"key":"1372_CR13","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.chom.2023.05.012","volume":"31","author":"D Jochmans","year":"2023","unstructured":"Jochmans, D., Laporte, M. & Neyts, J. Antiviral strategies for epidemic and pandemic preparedness. Cell Host Microbe 31, 856\u2013860 (2023).","journal-title":"Cell Host Microbe"},{"key":"1372_CR14","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12985-025-02755-1","volume":"22","author":"B Qian","year":"2025","unstructured":"Qian, B. et al. EIDD-2801 resists to infection and co-infection of SARS-CoV-2 and influenza virus. Virol. J. 22, 126 (2025).","journal-title":"Virol. J."},{"key":"1372_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44339-z","volume":"15","author":"L-H Li","year":"2024","unstructured":"Li, L.-H. et al. Multiplexed multicolor antiviral assay amenable for high-throughput research. Nat. Commun. 15, 42 (2024).","journal-title":"Nat. Commun."},{"key":"1372_CR16","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-023-00692-8","volume":"22","author":"A von Delft","year":"2023","unstructured":"von Delft, A. et al. Accelerating antiviral drug discovery: lessons from COVID-19. Nat. Rev. Drug Discov. 22, 585\u2013603 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1372_CR17","first-page":"101451","volume":"19","author":"X Chan","year":"2027","unstructured":"Chan, X. et al. Accelerating the clinical development of drugs for dengue: WHO dengue therapeutics landscape analysis and target product profiles. Lancet Microbe 19, 101451 (2027).","journal-title":"Lancet Microbe"},{"key":"1372_CR18","doi-asserted-by":"publisher","first-page":"e64","DOI":"10.1016\/S1473-3099(15)00543-5","volume":"16","author":"CC Holm-Hansen","year":"2016","unstructured":"Holm-Hansen, C. C., Midgley, S. E. & Fischer, T. K. Global emergence of enterovirus D68: a systematic review. Lancet Infect. Dis. 16, e64\u2013e75 (2016).","journal-title":"Lancet Infect. Dis."},{"key":"1372_CR19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-020-0147-3","volume":"6","author":"ST Jacob","year":"2020","unstructured":"Jacob, S. T. et al. Ebola virus disease. Nat. Rev. Dis. Primers 6, 13 (2020).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"1372_CR20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s44298-024-00081-x","volume":"2","author":"M Halbrook","year":"2024","unstructured":"Halbrook, M. et al. Mpox in Central Africa: complex epidemiology requires a constellation approach. npj Viruses 2, 69 (2024).","journal-title":"npj Viruses"},{"key":"1372_CR21","doi-asserted-by":"publisher","first-page":"e271","DOI":"10.1016\/S1473-3099(26)00283-5","volume":"26","author":"O Mitj\u00e0","year":"2026","unstructured":"Mitj\u00e0, O. Andes virus on a cruise ship: person-to-person transmission and an empty pipeline. Lancet Infect. Dis. 26, e271\u2013e272 (2026).","journal-title":"Lancet Infect. Dis."},{"key":"1372_CR22","doi-asserted-by":"publisher","first-page":"100549","DOI":"10.1016\/j.xcrm.2022.100549","volume":"3","author":"M Singh","year":"2022","unstructured":"Singh, M. & de Wit, E. Antiviral agents for the treatment of COVID-19: progress and challenges. Cell Rep. Med. 3, 100549 (2022).","journal-title":"Cell Rep. Med."},{"key":"1372_CR23","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1056\/NEJMoa2509306","volume":"394","author":"FG Hayden","year":"2026","unstructured":"Hayden, F. G. et al. Ensitrelvir for Covid-19 postexposure prophylaxis in household contacts. N. Engl. J. Med. 394, 1905\u20131915 (2026).","journal-title":"N. Engl. J. Med."},{"key":"1372_CR24","doi-asserted-by":"publisher","first-page":"5001","DOI":"10.1021\/acs.jmedchem.1c00071","volume":"64","author":"RL Mackman","year":"2021","unstructured":"Mackman, R. L. et al. Prodrugs of a 1\u2032-CN-4-Aza-7,9-dideazaadenosine C-nucleoside leading to the discovery of remdesivir (GS-5734) as a potent inhibitor of respiratory syncytial virus with efficacy in the African green monkey model of RSV. J. Med. Chem. 64, 5001\u20135017 (2021). This paper describes the synthesis and discovery of remdesivir and its therapeutic efficacy against RSV in non-human primates.","journal-title":"J. Med. Chem."},{"key":"1372_CR25","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1021\/acscentsci.0c00489","volume":"6","author":"RT Eastman","year":"2020","unstructured":"Eastman, R. T. et al. Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS Cent. Sci. 6, 672\u2013683 (2020).","journal-title":"ACS Cent. Sci."},{"key":"1372_CR26","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nature17180","volume":"531","author":"TK Warren","year":"2016","unstructured":"Warren, T. K. et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 531, 381\u2013385 (2016).","journal-title":"Nature"},{"key":"1372_CR27","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal3653","volume":"9","author":"TP Sheahan","year":"2017","unstructured":"Sheahan, T. P. et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci. Transl. Med. 9, eaal3653 (2017). This paper exemplifies how the antiviral activity of existing drugs could be systematically assessed against viruses with epidemic or pandemic potential.","journal-title":"Sci. Transl. Med."},{"key":"1372_CR28","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.ijid.2020.02.018","volume":"93","author":"PI Andersen","year":"2020","unstructured":"Andersen, P. I. et al. Discovery and development of safe-in-man broad-spectrum antiviral agents. Int. J. Infect. Dis. 93, 268\u2013276 (2020).","journal-title":"Int. J. Infect. Dis."},{"key":"1372_CR29","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom, S. et al. Drug repurposing: progress, challenges and recommendations. Nat. Rev. Drug Discov. 18, 41\u201358 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1372_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103288","volume":"66","author":"L Liesenborghs","year":"2021","unstructured":"Liesenborghs, L. et al. Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial. eBioMedicine 66, 103288 (2021).","journal-title":"eBioMedicine"},{"key":"1372_CR31","doi-asserted-by":"publisher","first-page":"1072202","DOI":"10.3389\/fphar.2022.1072202","volume":"13","author":"R Abdelnabi","year":"2022","unstructured":"Abdelnabi, R., Maes, P., de Jonghe, S., Weynand, B. & Neyts, J. Combination of the parent analogue of remdesivir (GS-441524) and molnupiravir results in a markedly potent antiviral effect in SARS-CoV-2 infected Syrian hamsters. Front. Pharmacol. 13, 1072202 (2022).","journal-title":"Front. Pharmacol."},{"key":"1372_CR32","doi-asserted-by":"publisher","first-page":"1165208","DOI":"10.3389\/fmolb.2023.1165208","volume":"10","author":"KMP Das","year":"2023","unstructured":"Das, K. M. P. Editorial: antiviral drug discovery against pathogens of pandemic concern: advancements in target site identification and structure-based drug development. Front. Mol. Biosci. 10, 1165208 (2023).","journal-title":"Front. Mol. Biosci."},{"key":"1372_CR33","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/s41586-021-03990-6","volume":"598","author":"SJF Kaptein","year":"2021","unstructured":"Kaptein, S. J. F. et al. A pan-serotype dengue virus inhibitor targeting the NS3-NS4B interaction. Nature 598, 504\u2013509 (2021). This paper reports the discovery and molecular mechanism of a first-in-class pan-serotype inhibitor of dengue virus, demonstrating that it blocks the de novo formation of the NS3\u2013NS4B complex.","journal-title":"Nature"},{"key":"1372_CR34","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nature08960","volume":"465","author":"M Gao","year":"2010","unstructured":"Gao, M. et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465, 96\u2013100 (2010). This study exemplifies how phenotypic drug discovery can identify potent inhibitors of viral proteins lacking enzymatic activity, leading to the discovery of NS5A inhibitors that now form a cornerstone of combination therapies for hepatitis C virus infection.","journal-title":"Nature"},{"key":"1372_CR35","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/s41586-025-08773-x","volume":"640","author":"M Laporte","year":"2025","unstructured":"Laporte, M. et al. A coronavirus assembly inhibitor that targets the viral membrane protein. Nature 640, 514\u2013523 (2025). Discovery of coronavirus assembly as a druggable target by blocking M- protein oligomerization and subsequent membrane curvature.","journal-title":"Nature"},{"key":"1372_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2025.106103","volume":"236","author":"A-B Bl\u00e1zquez","year":"2025","unstructured":"Bl\u00e1zquez, A.-B. et al. Lipid-targeting antiviral strategies: current state and future perspectives. Antivir. Res. 236, 106103 (2025).","journal-title":"Antivir. Res."},{"key":"1372_CR37","doi-asserted-by":"publisher","first-page":"7276","DOI":"10.3390\/ijms26157276","volume":"26","author":"MS Krasilnikov","year":"2025","unstructured":"Krasilnikov, M. S., Denisov, V. S., Korshun, V. A., Ustinov, A. V. & Alferova, V. A. Membrane-targeting antivirals. Int. J. Mol. Sci. 26, 7276 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"1372_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.70563","volume":"97","author":"L Dsouza","year":"2025","unstructured":"Dsouza, L. & Yang, Z. Viral reprogramming of nucleotide synthesis and its impact on viral infection. J. Med. Virol. 97, e70563 (2025).","journal-title":"J. Med. Virol."},{"key":"1372_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113201","volume":"213","author":"L Tian","year":"2021","unstructured":"Tian, L. et al. RNA-dependent RNA polymerase (RdRp) inhibitors: the current landscape and repurposing for the COVID-19 pandemic. Eur. J. Med. Chem. 213, 113201 (2021).","journal-title":"Eur. J. Med. Chem."},{"key":"1372_CR40","doi-asserted-by":"publisher","first-page":"veac082","DOI":"10.1093\/ve\/veac082","volume":"8","author":"J Charon","year":"2022","unstructured":"Charon, J., Buchmann, J. P., Sadiq, S. & Holmes, E. C. RdRp-scan: a bioinformatic resource to identify and annotate divergent RNA viruses in metagenomic sequence data. Virus Evol. 8, veac082 (2022).","journal-title":"Virus Evol."},{"key":"1372_CR41","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.3389\/fmicb.2019.01945","volume":"10","author":"H Jia","year":"2019","unstructured":"Jia, H. & Gong, P. A structure-function diversity survey of the RNA-dependent RNA polymerases from the positive-strand RNA viruses. Front. Microbiol. 10, 1945 (2019).","journal-title":"Front. Microbiol."},{"key":"1372_CR42","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.1007\/s00018-014-1695-z","volume":"71","author":"AJW te Velthuis","year":"2014","unstructured":"te Velthuis, A. J. W. Common and unique features of viral RNA-dependent polymerases. Cell. Mol. Life Sci. 71, 4403\u20134420 (2014). Key review (together with reference 33) that summarizes shared and distinct features of viral RNA polymerases.","journal-title":"Cell. Mol. Life Sci."},{"key":"1372_CR43","doi-asserted-by":"crossref","unstructured":"Ferrero, D., Ferrer-Orta, C. & Verdaguer, N. Viral RNA-dependent RNA polymerases: a structural overview. In Virus Protein and Nucleoprotein Complexes (eds Harris, J. R. & Bhella, D.) 39\u201371 (Springer, 2018).","DOI":"10.1007\/978-981-10-8456-0_3"},{"key":"1372_CR44","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41586-020-2368-8","volume":"584","author":"HS Hillen","year":"2020","unstructured":"Hillen, H. S. et al. Structure of replicating SARS-CoV-2 polymerase. Nature 584, 154\u2013156 (2020).","journal-title":"Nature"},{"key":"1372_CR45","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s41579-020-00501-8","volume":"19","author":"AJW Te Velthuis","year":"2021","unstructured":"Te Velthuis, A. J. W., Grimes, J. M. & Fodor, E. Structural insights into RNA polymerases of negative-sense RNA viruses. Nat. Rev. Microbiol. 19, 303\u2013318 (2021).","journal-title":"Nat. Rev. Microbiol."},{"key":"1372_CR46","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.3390\/v14102200","volume":"14","author":"K Ramaswamy","year":"2022","unstructured":"Ramaswamy, K., Rashid, M., Ramasamy, S., Jayavelu, T. & Venkataraman, S. Revisiting viral RNA-dependent RNA polymerases: insights from recent structural studies. Viruses 14, 2200 (2022).","journal-title":"Viruses"},{"key":"1372_CR47","doi-asserted-by":"publisher","first-page":"204020662097678","DOI":"10.1177\/2040206620976786","volume":"28","author":"J Huchting","year":"2020","unstructured":"Huchting, J. Targeting viral genome synthesis as broad-spectrum approach against RNA virus infections. Antivir. Chem. Chemother. 28, 2040206620976786 (2020).","journal-title":"Antivir. Chem. Chemother."},{"key":"1372_CR48","doi-asserted-by":"publisher","first-page":"661","DOI":"10.3390\/ph17050661","volume":"17","author":"D Palazzotti","year":"2024","unstructured":"Palazzotti, D. et al. Small molecule drugs targeting viral polymerases. Pharmaceuticals 17, 661 (2024).","journal-title":"Pharmaceuticals"},{"key":"1372_CR49","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1021\/acs.jmedchem.7b00734","volume":"61","author":"Y Mehellou","year":"2018","unstructured":"Mehellou, Y., Rattan, H. S. & Balzarini, J. The protide prodrug technology: from the concept to the clinic. J. Med. Chem. 61, 2211\u20132226 (2018).","journal-title":"J. Med. Chem."},{"key":"1372_CR50","doi-asserted-by":"publisher","first-page":"105501","DOI":"10.1016\/j.antiviral.2022.105501","volume":"210","author":"A Shannon","year":"2023","unstructured":"Shannon, A. & Canard, B. Kill or corrupt: mechanisms of action and drug-resistance of nucleotide analogues against SARS-CoV-2. Antivir. Res. 210, 105501 (2023).","journal-title":"Antivir. Res."},{"key":"1372_CR51","doi-asserted-by":"publisher","first-page":"100770","DOI":"10.1016\/j.jbc.2021.100770","volume":"297","author":"CJ Gordon","year":"2021","unstructured":"Gordon, C. J., Tchesnokov, E. P., Schinazi, R. F. & G\u00f6tte, M. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. J. Biol. Chem. 297, 100770 (2021).","journal-title":"J. Biol. Chem."},{"key":"1372_CR52","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41594-021-00651-0","volume":"28","author":"F Kabinger","year":"2021","unstructured":"Kabinger, F. et al. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat. Struct. Mol. Biol. 28, 740\u2013746 (2021).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"1372_CR53","doi-asserted-by":"publisher","first-page":"26955","DOI":"10.1073\/pnas.2014441117","volume":"117","author":"SJF Kaptein","year":"2020","unstructured":"Kaptein, S. J. F. et al. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity. Proc. Natl Acad. Sci. USA 117, 26955\u201326965 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1372_CR54","doi-asserted-by":"publisher","first-page":"7202","DOI":"10.1021\/jm100863x","volume":"53","author":"MJ Sofia","year":"2010","unstructured":"Sofia, M. J. et al. Discovery of a \u03b2-d-2\u2032-deoxy-2\u2032-\u03b1-fluoro-2\u2032-\u03b2-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J. Med. Chem. 53, 7202\u20137218 (2010).","journal-title":"J. Med. Chem."},{"key":"1372_CR55","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1128\/AAC.00054-12","volume":"56","author":"AM Lam","year":"2012","unstructured":"Lam, A. M. et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob. Agents Chemother. 56, 3359\u20133368 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1372_CR56","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.jhep.2020.05.020","volume":"73","author":"M Cornberg","year":"2020","unstructured":"Cornberg, M. et al. Sofosbuvir monotherapy fails to achieve HEV RNA elimination in patients with chronic hepatitis E - the HepNet SofE pilot study. J. Hepatol. 73, 696\u2013699 (2020).","journal-title":"J. Hepatol."},{"key":"1372_CR57","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01389-18","volume":"63","author":"AC Ferreira","year":"2019","unstructured":"Ferreira, A. C. et al. Beyond members of the Flaviviridae family, sofosbuvir also inhibits chikungunya virus replication. Antimicrob. Agents Chemother. 63, e01389-18 (2019).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1372_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2023.578148","volume":"381","author":"A Medina","year":"2023","unstructured":"Medina, A. et al. Treatment with sofosbuvir attenuates the adverse neurodevelopmental consequences of Zika virus infection in infant rhesus macaques. J. Neuroimmunol. 381, 578148 (2023).","journal-title":"J. Neuroimmunol."},{"key":"1372_CR59","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1056\/NEJMp2032369","volume":"383","author":"D Rubin","year":"2020","unstructured":"Rubin, D., Chan-Tack, K., Farley, J. & Sherwat, A. FDA approval of remdesivir \u2014 a step in the right direction. N. Engl. J. Med. 383, 2598\u20132600 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1372_CR60","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1021\/acsmedchemlett.1c00624","volume":"13","author":"RL Mackman","year":"2022","unstructured":"Mackman, R. L. Phosphoramidate prodrugs continue to deliver, the journey of remdesivir (GS-5734) from RSV to SARS-CoV-2. ACS Med. Chem. Lett. 13, 338\u2013347 (2022).","journal-title":"ACS Med. Chem. Lett."},{"key":"1372_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52071-5","volume":"15","author":"Y Lin","year":"2024","unstructured":"Lin, Y. et al. A robust mouse model of HPIV-3 infection and efficacy of GS-441524 against virus-induced lung pathology. Nat. Commun. 15, 7765 (2024).","journal-title":"Nat. Commun."},{"key":"1372_CR62","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau9242","volume":"11","author":"MK Lo","year":"2019","unstructured":"Lo, M. K. et al. Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge. Sci. Transl. Med. 11, eaau9242 (2019).","journal-title":"Sci. Transl. Med."},{"key":"1372_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2019.104541","volume":"169","author":"AJ Brown","year":"2019","unstructured":"Brown, A. J. et al. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antivir. Res. 169, 104541 (2019).","journal-title":"Antivir. Res."},{"key":"1372_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-29517-9","volume":"13","author":"SR Radoshitzky","year":"2023","unstructured":"Radoshitzky, S. R. et al. Expanded profiling of remdesivir as a broad-spectrum antiviral and low potential for interaction with other medications in vitro. Sci. Rep. 13, 3131 (2023).","journal-title":"Sci. Rep."},{"key":"1372_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/srep43395","volume":"7","author":"MK Lo","year":"2017","unstructured":"Lo, M. K. et al. GS-5734 and its parent nucleoside analog inhibit filo-, pneumo-, and paramyxoviruses. Sci. Rep. 7, 43395 (2017).","journal-title":"Sci. Rep."},{"key":"1372_CR66","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/cpt.2251","volume":"111","author":"M Ueda","year":"2022","unstructured":"Ueda, M., Tanimoto, T., Murayama, A., Ozaki, A. & Kami, M. Japan\u2019s drug regulation during the COVID-19 pandemic: lessons from a case study of favipiravir. Clin. Pharmacol. Ther. 111, 545\u2013547 (2022).","journal-title":"Clin. Pharmacol. Ther."},{"key":"1372_CR67","doi-asserted-by":"publisher","first-page":"107512","DOI":"10.1016\/j.pharmthera.2020.107512","volume":"209","author":"K Shiraki","year":"2020","unstructured":"Shiraki, K. & Daikoku, T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol. Ther. 209, 107512 (2020).","journal-title":"Pharmacol. Ther."},{"key":"1372_CR68","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1093\/infdis\/jiac135","volume":"226","author":"FG Hayden","year":"2022","unstructured":"Hayden, F. G. et al. Favipiravir treatment of uncomplicated influenza in adults: results of two phase 3, randomized, double-blind, placebo-controlled trials. J. Infect. Dis. 226, 1790\u20131799 (2022).","journal-title":"J. Infect. Dis."},{"key":"1372_CR69","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.antiviral.2018.03.003","volume":"153","author":"L Delang","year":"2018","unstructured":"Delang, L., Abdelnabi, R. & Neyts, J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antivir. Res. 153, 85\u201394 (2018).","journal-title":"Antivir. Res."},{"key":"1372_CR70","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1038\/s41591-026-04402-w","volume":"32","author":"C Erameh","year":"2026","unstructured":"Erameh, C. et al. Favipiravir for Lassa fever: an open-label, randomized controlled phase 2 trial. Nat. Med. 32, 2522\u20132532 (2026).","journal-title":"Nat. Med."},{"key":"1372_CR71","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-3980-9","volume":"19","author":"JS Lee","year":"2019","unstructured":"Lee, J. S. et al. Anti-Ebola therapy for patients with Ebola virus disease: a systematic review. BMC Infect. Dis. 19, 376 (2019).","journal-title":"BMC Infect. Dis."},{"key":"1372_CR72","volume":"15","author":"S Batool","year":"2023","unstructured":"Batool, S. et al. Efficacy and safety of favipiravir in treating COVID-19 patients: a meta-analysis of randomized control trials. Cureus 15, e33676 (2023).","journal-title":"Cureus"},{"key":"1372_CR73","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1093\/infdis\/jiab247","volume":"224","author":"S Zhou","year":"2021","unstructured":"Zhou, S. et al. \u03b2-d-N4-hydroxycytidine inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells. J. Infect. Dis. 224, 415\u2013419 (2021).","journal-title":"J. Infect. Dis."},{"key":"1372_CR74","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aax5866","volume":"11","author":"M Toots","year":"2019","unstructured":"Toots, M. et al. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci. Transl. Med. 11, eaax5866 (2019). This paper describes the discovery of molnupiravir as a potent and bioavailable RdRp inhibitor of influenza A and B viruses.","journal-title":"Sci. Transl. Med."},{"key":"1372_CR75","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00766-18","volume":"62","author":"J-J Yoon","year":"2018","unstructured":"Yoon, J.-J. et al. Orally efficacious broad-spectrum ribonucleoside analog inhibitor of influenza and respiratory syncytial viruses. Antimicrob. Agents Chemother. 62, e00766-18 (2018).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1372_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2019.104597","volume":"171","author":"GR Painter","year":"2019","unstructured":"Painter, G. R. et al. The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal Venezuelan equine encephalitis virus infection. Antivir. Res. 171, 104597 (2019).","journal-title":"Antivir. Res."},{"key":"1372_CR77","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.virs.2023.05.011","volume":"38","author":"Z Wang","year":"2023","unstructured":"Wang, Z. et al. In vitro and in vivo efficacy of molnupiravir against Zika virus infections. Virol. Sin. 38, 639\u2013642 (2023).","journal-title":"Virol. Sin."},{"key":"1372_CR78","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.coviro.2021.06.003","volume":"50","author":"GR Painter","year":"2021","unstructured":"Painter, G. R., Natchus, M. G., Cohen, O., Holman, W. & Painter, W. P. Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19. Curr. Opin. Virol. 50, 17\u201322 (2021).","journal-title":"Curr. Opin. Virol."},{"key":"1372_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2024.105839","volume":"223","author":"N Santos-Ferreira","year":"2024","unstructured":"Santos-Ferreira, N. et al. Molnupiravir inhibits human norovirus and rotavirus replication in 3D human intestinal enteroids. Antivir. Res. 223, 105839 (2024).","journal-title":"Antivir. Res."},{"key":"1372_CR80","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1128\/AAC.47.1.244-254.2003","volume":"47","author":"LJ Stuyver","year":"2003","unstructured":"Stuyver, L. J. et al. Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture. Antimicrob. Agents Chemother. 47, 244\u2013254 (2003).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1372_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2022.105453","volume":"209","author":"GR Bluemling","year":"2023","unstructured":"Bluemling, G. R. et al. The prophylactic and therapeutic efficacy of the broadly active antiviral ribonucleoside N4-hydroxycytidine (EIDD-1931) in a mouse model of lethal Ebola virus infection. Antivir. Res. 209, 105453 (2023).","journal-title":"Antivir. Res."},{"key":"1372_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2022.105273","volume":"199","author":"Q Wang","year":"2022","unstructured":"Wang, Q. et al. In vitro and in vivo efficacy of a novel nucleoside analog H44 against Crimean-Congo hemorrhagic fever virus. Antivir. Res. 199, 105273 (2022).","journal-title":"Antivir. Res."},{"key":"1372_CR83","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41586-023-06649-6","volume":"623","author":"T Sanderson","year":"2023","unstructured":"Sanderson, T. et al. A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes. Nature 623, 594\u2013600 (2023).","journal-title":"Nature"},{"key":"1372_CR84","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/nature13027","volume":"508","author":"TK Warren","year":"2014","unstructured":"Warren, T. K. et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 508, 402\u2013405 (2014).","journal-title":"Nature"},{"key":"1372_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2021.105180","volume":"195","author":"JG Julander","year":"2021","unstructured":"Julander, J. G. et al. An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral. Antivir. Res. 195, 105180 (2021).","journal-title":"Antivir. Res."},{"key":"1372_CR86","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28113-1","volume":"13","author":"A Shannon","year":"2022","unstructured":"Shannon, A. et al. A dual mechanism of action of AT-527 against SARS-CoV-2 polymerase. Nat. Commun. 13, 621 (2022).","journal-title":"Nat. Commun."},{"key":"1372_CR87","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.70170","volume":"66","author":"X-J Zhou","year":"2026","unstructured":"Zhou, X.-J. et al. In vitro and clinical evaluation of potential interactions of bemnifosbuvir with drug-metabolizing enzymes. J. Clin. Pharmacol. 66, e70170 (2026).","journal-title":"J. Clin. Pharmacol."},{"key":"1372_CR88","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01201-19","author":"E Berliba","year":"2019","unstructured":"Berliba, E. et al. Safety, pharmacokinetics, and antiviral activity of AT-527, a novel purine nucleotide prodrug, in hepatitis C virus-infected subjects with or without cirrhosis. Antimicrob. Agents Chemother. https:\/\/doi.org\/10.1128\/aac.01201-19 (2019).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1372_CR89","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0227104","volume":"15","author":"SS Good","year":"2020","unstructured":"Good, S. S., Moussa, A., Zhou, X.-J., Pietropaolo, K. & Sommadossi, J.-P. Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus. PLoS ONE 15, e0227104 (2020).","journal-title":"PLoS ONE"},{"key":"1372_CR90","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2025-336714","author":"J Hu","year":"2026","unstructured":"Hu, J. et al. Nucleotide analogue bemnifosbuvir inhibits hepatitis E virus replication in preclinical models. Gut https:\/\/doi.org\/10.1136\/gutjnl-2025-336714 (2026).","journal-title":"Gut"},{"key":"1372_CR91","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02479-20","author":"SS Good","year":"2021","unstructured":"Good, S. S. et al. AT-527, a double prodrug of a guanosine nucleotide analog, is a potent inhibitor of SARS-CoV-2 in vitro and a promising oral antiviral for treatment of COVID-19. Antimicrob. Agents Chemother. https:\/\/doi.org\/10.1128\/aac.02479-20 (2021).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1372_CR92","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1126\/science.abj5508","volume":"375","author":"J Sourimant","year":"2022","unstructured":"Sourimant, J. et al. 4\u2032-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication. Science 375, 161\u2013167 (2022). This paper describes the discovery of 4\u2032-fluorouridine as an inhibitor of the RdRp of RSV, several members of the Paramyxoviridae family and SARS-CoV-2.","journal-title":"Science"},{"key":"1372_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2024.106046","volume":"233","author":"L Schrell","year":"2025","unstructured":"Schrell, L. et al. Inhibitors of dihydroorotate dehydrogenase synergize with the broad antiviral activity of 4\u2032-fluorouridine. Antivir. Res. 233, 106046 (2025).","journal-title":"Antivir. Res."},{"key":"1372_CR94","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ado7034","volume":"16","author":"SR Welch","year":"2024","unstructured":"Welch, S. R. et al. Delayed low-dose oral administration of 4\u2032-fluorouridine inhibits pathogenic arenaviruses in animal models of lethal disease. Sci. Transl. Med. 16, eado7034 (2024).","journal-title":"Sci. Transl. Med."},{"key":"1372_CR95","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1014093","volume":"22","author":"O Escaffre","year":"2026","unstructured":"Escaffre, O. et al. Efficacy of the nucleoside analog 4\u2032-fluorouridine against Nipah virus in the Syrian hamster model. PLoS Pathog. 22, e1014093 (2026).","journal-title":"PLoS Pathog."},{"key":"1372_CR96","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1011342","volume":"19","author":"CM Lieber","year":"2023","unstructured":"Lieber, C. M. et al. 4\u2019-Fluorouridine mitigates lethal infection with pandemic human and highly pathogenic avian influenza viruses. PLOS Pathog. 19, e1011342 (2023).","journal-title":"PLOS Pathog."},{"key":"1372_CR97","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.00420-24","volume":"15","author":"P Yin","year":"2024","unstructured":"Yin, P. et al. 4\u2032-Fluorouridine inhibits alphavirus replication and infection in vitro and in vivo. mBio 15, e00420-24 (2024).","journal-title":"mBio"},{"key":"1372_CR98","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01541-25","volume":"100","author":"J Wong","year":"2026","unstructured":"Wong, J. et al. Impact of mutations affecting 4\u2032-fluorouridine susceptibility on fitness and treatment outcomes for Venezuelan equine encephalitis virus. J. Virol. 100, e0154125 (2026).","journal-title":"J. Virol."},{"key":"1372_CR99","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jhep.2025.06.022","volume":"83","author":"L Sandmann","year":"2025","unstructured":"Sandmann, L. From HCV to HEV: repurposing a nucleoside analogue for hepatitis E therapy. J. Hepatol. 83, 989\u2013991 (2025).","journal-title":"J. Hepatol."},{"key":"1372_CR100","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1053\/j.gastro.2024.10.043","volume":"168","author":"X Zhang","year":"2025","unstructured":"Zhang, X. et al. A pangenotypic hepatitis E virus replication inhibitor with high potency in a rat infection model. Gastroenterology 168, 769\u2013783.e12 (2025).","journal-title":"Gastroenterology"},{"key":"1372_CR101","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1021\/jm5017279","volume":"58","author":"G Wang","year":"2015","unstructured":"Wang, G. et al. Discovery of 4\u2032-chloromethyl-2\u2032-deoxy-3\u2032,5\u2032-di-O-isobutyryl-2\u2032-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection. J. Med. Chem. 58, 1862\u20131878 (2015).","journal-title":"J. Med. Chem."},{"key":"1372_CR102","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004995","volume":"11","author":"J Deval","year":"2015","unstructured":"Deval, J. et al. Molecular basis for the selective inhibition of respiratory syncytial virus RNA polymerase by 2\u2032-fluoro-4\u2032-chloromethyl-cytidine triphosphate. PLoS Pathog. 11, e1004995 (2015).","journal-title":"PLoS Pathog."},{"key":"1372_CR103","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1056\/NEJMoa1413275","volume":"373","author":"JP DeVincenzo","year":"2015","unstructured":"DeVincenzo, J. P. et al. Activity of oral ALS-008176 in a respiratory syncytial virus challenge study. N. Engl. J. Med. 373, 2048\u20132058 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1372_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104712","volume":"175","author":"MK Lo","year":"2020","unstructured":"Lo, M. K. et al. Potent in vitro activity of \u03b2-D-4\u2032-chloromethyl-2\u2032-deoxy-2\u2032-fluorocytidine against Nipah virus. Antivir. Res. 175, 104712 (2020).","journal-title":"Antivir. Res."},{"key":"1372_CR105","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1081\/NCN-200060112","volume":"24","author":"C Pierra","year":"2005","unstructured":"Pierra, C. et al. Nm 283, an efficient prodrug of the potent anti-HCV agent 2\u2032-C-methylcytidine. Nucleosides Nucleotides Nucleic Acids 24, 767\u2013770 (2005).","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"1372_CR106","doi-asserted-by":"publisher","first-page":"6614","DOI":"10.1021\/jm0603623","volume":"49","author":"C Pierra","year":"2006","unstructured":"Pierra, C. et al. Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2\u2032-C-methylcytidine. J. Med. Chem. 49, 6614\u20136620 (2006).","journal-title":"J. Med. Chem."},{"key":"1372_CR107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.antiviral.2015.01.002","volume":"116","author":"J-C Lee","year":"2015","unstructured":"Lee, J.-C. et al. Characterization of the activity of 2\u2032-C-methylcytidine against dengue virus replication. Antivir. Res. 116, 1\u20139 (2015).","journal-title":"Antivir. Res."},{"key":"1372_CR108","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.bbrc.2012.10.003","volume":"427","author":"J Rocha-Pereira","year":"2012","unstructured":"Rocha-Pereira, J. et al. Inhibition of norovirus replication by the nucleoside analogue 2\u2032-C-methylcytidine. Biochem. Biophys. Res. Commun. 427, 796\u2013800 (2012).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1372_CR109","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1093\/infdis\/jiy398","volume":"218","author":"J Van Dycke","year":"2018","unstructured":"Van Dycke, J. et al. A single nucleoside viral polymerase inhibitor against norovirus, rotavirus, and sapovirus-induced diarrhea. J. Infect. Dis. 218, 1753\u20131758 (2018).","journal-title":"J. Infect. Dis."},{"key":"1372_CR110","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adz5913","volume":"11","author":"F Amblard","year":"2025","unstructured":"Amblard, F. et al. 1\u2032-Cyanocytidine-5\u2032-isobutyryl is a potent SARS-CoV-2 inhibitor in culture and infected Syrian hamsters. Sci. Adv. 11, eadz5913 (2025).","journal-title":"Sci. Adv."},{"key":"1372_CR111","doi-asserted-by":"publisher","first-page":"5255","DOI":"10.1021\/acs.jcim.5c00376","volume":"65","author":"H Luo","year":"2025","unstructured":"Luo, H., Ran, T., Wang, L. & Chen, H. NA-DB: an online database of nucleoside analogues. J. Chem. Inf. Model. 65, 5255\u20135272 (2025).","journal-title":"J. Chem. Inf. Model."},{"key":"1372_CR112","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1038\/s41564-020-0752-7","volume":"5","author":"RM Cox","year":"2020","unstructured":"Cox, R. M. et al. Orally efficacious broad-spectrum allosteric inhibitor of paramyxovirus polymerase. Nat. Microbiol. 5, 1232\u20131246 (2020). This work demonstrates that conserved allosteric sites on the paramyxovirus RdRp can be exploited to achieve orally active, broader-spectrum antiviral inhibition.","journal-title":"Nat. Microbiol."},{"key":"1372_CR113","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aef1594","volume":"12","author":"CM Lieber","year":"2026","unstructured":"Lieber, C. M. et al. Developmental candidate GHP-88310\/EIDD-3608 with high tolerability and oral efficacy in measles and respiratory paramyxovirus models. Sci. Adv. 12, eaef1594 (2026).","journal-title":"Sci. Adv."},{"key":"1372_CR114","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s42003-023-04990-0","volume":"6","author":"VA Kleiner","year":"2023","unstructured":"Kleiner, V. A. et al. Conserved allosteric inhibitory site on the respiratory syncytial virus and human metapneumovirus RNA-dependent RNA polymerases. Commun. Biol. 6, 649 (2023).","journal-title":"Commun. Biol."},{"key":"1372_CR115","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.3389\/fmicb.2020.01440","volume":"11","author":"D Yi","year":"2020","unstructured":"Yi, D. et al. Identification of a broad-spectrum viral inhibitor targeting a novel allosteric site in the RNA-dependent RNA polymerases of dengue virus and norovirus. Front. Microbiol. 11, 1440 (2020).","journal-title":"Front. Microbiol."},{"key":"1372_CR116","doi-asserted-by":"publisher","first-page":"5172","DOI":"10.1021\/acs.jmedchem.5b01697","volume":"59","author":"AK Ghosh","year":"2016","unstructured":"Ghosh, A. K., Osswald, H. L. & Prato, G. Recent progress in the development of HIV-1 protease inhibitors for the treatment of HIV\/AIDS. J. Med. Chem. 59, 5172\u20135208 (2016).","journal-title":"J. Med. Chem."},{"key":"1372_CR117","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/bs.enz.2021.09.004","volume":"50","author":"J Zephyr","year":"2021","unstructured":"Zephyr, J., Kurt Yilmaz, N. & Schiffer, C. A. Viral proteases: structure, mechanism and inhibition. Enzymes 50, 301\u2013333 (2021).","journal-title":"Enzymes"},{"key":"1372_CR118","doi-asserted-by":"publisher","first-page":"6099","DOI":"10.1021\/ja076558p","volume":"130","author":"MD Altman","year":"2008","unstructured":"Altman, M. D. et al. HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants. J. Am. Chem. Soc. 130, 6099\u20136113 (2008).","journal-title":"J. Am. Chem. Soc."},{"key":"1372_CR119","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1021\/acs.jmedchem.3c01971","volume":"67","author":"SD Martino","year":"2024","unstructured":"Martino, S. D., Petri, G. L. & De Rosa, M. Hepatitis C: the story of a long journey through first, second, and third generation NS3\/4A peptidomimetic inhibitors. What did we learn? J. Med. Chem. 67, 885\u2013921 (2024).","journal-title":"J. Med. Chem."},{"key":"1372_CR120","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/s41573-022-00542-z","volume":"21","author":"L Boike","year":"2022","unstructured":"Boike, L., Henning, N. J. & Nomura, D. K. Advances in covalent drug discovery. Nat. Rev. Drug Discov. 21, 881\u2013898 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1372_CR121","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s10930-020-09884-2","volume":"39","author":"A Aljoundi","year":"2020","unstructured":"Aljoundi, A., Bjij, I., El Rashedy, A. & Soliman, M. E. S. Covalent versus non-covalent enzyme inhibition: which route should we take? A justification of the good and bad from molecular modelling perspective. Protein J. 39, 97\u2013105 (2020).","journal-title":"Protein J."},{"key":"1372_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104900","volume":"182","author":"WW Phoo","year":"2020","unstructured":"Phoo, W. W. et al. Crystal structures of full length DENV4 NS2B-NS3 reveal the dynamic interaction between NS2B and NS3. Antivir. Res. 182, 104900 (2020).","journal-title":"Antivir. Res."},{"key":"1372_CR123","doi-asserted-by":"publisher","first-page":"105878","DOI":"10.1016\/j.antiviral.2024.105878","volume":"226","author":"S Voss","year":"2024","unstructured":"Voss, S., Rademann, J. & Nitsche, C. Characterisation of ten NS2B-NS3 proteases: paving the way for pan-flavivirus drugs. Antivir. Res. 226, 105878 (2024).","journal-title":"Antivir. Res."},{"key":"1372_CR124","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s12551-019-00508-3","volume":"11","author":"C Nitsche","year":"2019","unstructured":"Nitsche, C. Proteases from dengue, West Nile and Zika viruses as drug targets. Biophys. Rev. 11, 157\u2013165 (2019).","journal-title":"Biophys. Rev."},{"key":"1372_CR125","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1126\/science.abl4784","volume":"374","author":"DR Owen","year":"2021","unstructured":"Owen, D. R. et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science 374, 1586\u20131593 (2021). This paper describes the discovery and characterization of the protease inhibitor nirmatrelvir, highlighting how previous knowledge facilitated rapid drug development during the SARS-CoV-2 pandemic.","journal-title":"Science"},{"key":"1372_CR126","doi-asserted-by":"publisher","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","volume":"65","author":"Y Unoh","year":"2022","unstructured":"Unoh, Y. et al. Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19. J. Med. Chem. 65, 6499\u20136512 (2022).","journal-title":"J. Med. Chem."},{"key":"1372_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2023.105555","volume":"211","author":"J Li","year":"2023","unstructured":"Li, J. et al. Nirmatrelvir exerts distinct antiviral potency against different human coronaviruses. Antivir. Res. 211, 105555 (2023).","journal-title":"Antivir. Res."},{"key":"1372_CR128","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s44298-024-00028-2","volume":"2","author":"L Krismer","year":"2024","unstructured":"Krismer, L. et al. Study of key residues in MERS-CoV and SARS-CoV-2 main proteases for resistance against clinically applied inhibitors nirmatrelvir and ensitrelvir. npj Viruses 2, 23 (2024).","journal-title":"npj Viruses"},{"key":"1372_CR129","doi-asserted-by":"publisher","first-page":"105819","DOI":"10.1016\/j.ebiom.2025.105819","volume":"118","author":"ML Baniecki","year":"2025","unstructured":"Baniecki, M. L. et al. Integrated virologic analysis of resistance to nirmatrelvir\/ritonavir in individuals across four phase 2\/3 clinical studies for the treatment of COVID-19. eBioMedicine 118, 105819 (2025).","journal-title":"eBioMedicine"},{"key":"1372_CR130","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2025.106118","volume":"236","author":"A Inoue","year":"2025","unstructured":"Inoue, A. et al. M49L and other drug resistance mutations emerging in individuals after administration of ensitrelvir in Japanese clinical settings. Antivir. Res. 236, 106118 (2025).","journal-title":"Antivir. Res."},{"key":"1372_CR131","doi-asserted-by":"publisher","first-page":"13550","DOI":"10.1021\/acs.jmedchem.3c02469","volume":"67","author":"CMN Allerton","year":"2024","unstructured":"Allerton, C. M. N. et al. A second-generation oral SARS-CoV-2 main protease inhibitor clinical candidate for the treatment of COVID-19. J. Med. Chem. 67, 13550\u201313571 (2024).","journal-title":"J. Med. Chem."},{"key":"1372_CR132","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1039\/D3MD00493G","volume":"15","author":"YL Janin","year":"2024","unstructured":"Janin, Y. L. On the origins of SARS-CoV-2 main protease inhibitors. RSC Med. Chem. 15, 81\u2013118 (2024).","journal-title":"RSC Med. Chem."},{"key":"1372_CR133","doi-asserted-by":"publisher","first-page":"9866","DOI":"10.3390\/ijms23179866","volume":"23","author":"NHC Loos","year":"2022","unstructured":"Loos, N. H. C., Beijnen, J. H. & Schinkel, A. H. The mechanism-based inactivation of CYP3A4 by ritonavir: what mechanism? Int. J. Mol. Sci. 23, 9866 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1372_CR134","doi-asserted-by":"publisher","first-page":"4316","DOI":"10.1021\/acs.jproteome.0c00430","volume":"19","author":"B Luan","year":"2020","unstructured":"Luan, B., Huynh, T., Cheng, X., Lan, G. & Wang, H.-R. Targeting proteases for treating COVID-19. J. Proteome Res. 19, 4316\u20134326 (2020).","journal-title":"J. Proteome Res."},{"key":"1372_CR135","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3390\/v11020197","volume":"11","author":"K-O Chang","year":"2019","unstructured":"Chang, K.-O., Kim, Y., Lovell, S., Rathnayake, A. D. & Groutas, W. C. Antiviral drug discovery: norovirus proteases and development of inhibitors. Viruses 11, 197 (2019).","journal-title":"Viruses"},{"key":"1372_CR136","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2174\/156802610790725470","volume":"10","author":"H Steuber","year":"2010","unstructured":"Steuber, H. & Hilgenfeld, R. Recent advances in targeting viral proteases for the discovery of novel antivirals. Curr. Top. Med. Chem. 10, 323\u2013345 (2010).","journal-title":"Curr. Top. Med. Chem."},{"key":"1372_CR137","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1021\/acs.jmedchem.0c02258","volume":"65","author":"W Dai","year":"2022","unstructured":"Dai, W. et al. Design, synthesis, and biological evaluation of peptidomimetic aldehydes as broad-spectrum inhibitors against enterovirus and SARS-CoV-2. J. Med. Chem. 65, 2794\u20132808 (2022).","journal-title":"J. Med. Chem."},{"key":"1372_CR138","doi-asserted-by":"publisher","first-page":"948553","DOI":"10.3389\/fchem.2022.948553","volume":"10","author":"K Bafna","year":"2022","unstructured":"Bafna, K., Cioffi, C. L., Krug, R. M. & Montelione, G. T. Structural similarities between SARS-CoV2 3CLpro and other viral proteases suggest potential lead molecules for developing broad spectrum antivirals. Front. Chem. 10, 948553 (2022).","journal-title":"Front. Chem."},{"key":"1372_CR139","doi-asserted-by":"publisher","first-page":"4675","DOI":"10.1128\/AAC.02546-13","volume":"58","author":"J Rocha-Pereira","year":"2014","unstructured":"Rocha-Pereira, J. et al. The enterovirus protease inhibitor rupintrivir exerts cross-genotypic anti-norovirus activity and clears cells from the norovirus replicon. Antimicrob. Agents Chemother. 58, 4675\u20134681 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1372_CR140","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1021\/acsinfecdis.4c00254","volume":"10","author":"DS Metibemu","year":"2024","unstructured":"Metibemu, D. S., Adeyinka, O. S., Falode, J., Crown, O. & Ogungbe, I. V. Inhibitors of the structural and nonstructural proteins of alphaviruses. ACS Infect. Dis. 10, 2507\u20132524 (2024).","journal-title":"ACS Infect. Dis."},{"key":"1372_CR141","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2025.106322","volume":"245","author":"JD Sears","year":"2026","unstructured":"Sears, J. D. et al. Novel computational pipeline to identify target sites for broad spectrum antiviral drugs. Antivir. Res. 245, 106322 (2026).","journal-title":"Antivir. Res."},{"key":"1372_CR142","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.virol.2022.12.002","volume":"578","author":"S Fieulaine","year":"2023","unstructured":"Fieulaine, S., Tubiana, T. & Bressanelli, S. De novo modelling of HEV replication polyprotein: five-domain breakdown and involvement of flexibility in functional regulation. Virology 578, 128\u2013140 (2023).","journal-title":"Virology"},{"key":"1372_CR143","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.antiviral.2018.10.008","volume":"160","author":"T Noshi","year":"2018","unstructured":"Noshi, T. et al. In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit. Antivir. Res. 160, 109\u2013117 (2018).","journal-title":"Antivir. Res."},{"key":"1372_CR144","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2039","volume":"29","author":"S ter Horst","year":"2019","unstructured":"ter Horst, S., Concei\u00e7\u00e3o-Neto, N., Neyts, J. & Rocha-Pereira, J. Structural and functional similarities in bunyaviruses: perspectives for pan-bunya antivirals. Rev. Med. Virol. 29, e2039 (2019).","journal-title":"Rev. Med. Virol."},{"key":"1372_CR145","doi-asserted-by":"publisher","first-page":"100486","DOI":"10.1016\/j.jbc.2021.100486","volume":"296","author":"B Todd","year":"2021","unstructured":"Todd, B., Tchesnokov, E. P. & G\u00f6tte, M. The active form of the influenza cap-snatching endonuclease inhibitor baloxavir marboxil is a tight binding inhibitor. J. Biol. Chem. 296, 100486 (2021). This paper identifies and characterizes baloxavir as an endonuclease inhibitor of influenza virus, validating the polymerase PA subunit as a clinically relevant antiviral target.","journal-title":"J. Biol. Chem."},{"key":"1372_CR146","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.tim.2019.12.006","volume":"28","author":"S Olschewski","year":"2020","unstructured":"Olschewski, S., Cusack, S. & Rosenthal, M. The cap-snatching mechanism of bunyaviruses. Trends Microbiol. 28, 293\u2013303 (2020). This review focuses on the cap-snatching mechanism of bunyaviruses with a particular focus on recent structural and mechanistic data.","journal-title":"Trends Microbiol."},{"key":"1372_CR147","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-27890-4","volume":"8","author":"S Omoto","year":"2018","unstructured":"Omoto, S. et al. Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci. Rep. 8, 9633 (2018).","journal-title":"Sci. Rep."},{"key":"1372_CR148","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1038\/nrd.2018.219","volume":"17","author":"A Mullard","year":"2018","unstructured":"Mullard, A. FDA approves first new flu drug in 20 years. Nat. Rev. Drug Discov. 17, 853\u2013853 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1372_CR149","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1093\/jac\/dkaa337","volume":"75","author":"S Ter Horst","year":"2020","unstructured":"Ter Horst, S. et al. Enhanced efficacy of endonuclease inhibitor baloxavir acid against orthobunyaviruses when used in combination with ribavirin. J. Antimicrob. Chemother. 75, 3189\u20133193 (2020).","journal-title":"J. Antimicrob. Chemother."},{"key":"1372_CR150","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2206104119","volume":"119","author":"S Toba","year":"2022","unstructured":"Toba, S. et al. Identification of cap-dependent endonuclease inhibitors with broad-spectrum activity against bunyaviruses. Proc. Natl Acad. Sci. USA 119, e2206104119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1372_CR151","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00186-25","volume":"69","author":"K Konishi","year":"2025","unstructured":"Konishi, K. et al. A cap-dependent endonuclease inhibitor acts as a potent antiviral agent against La Crosse virus infection. Antimicrob. Agents Chemother. 69, e00186-25 (2025).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1372_CR152","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005636","volume":"12","author":"J Reguera","year":"2016","unstructured":"Reguera, J. et al. Comparative structural and functional analysis of bunyavirus and arenavirus cap-snatching endonucleases. PLoS Pathog. 12, e1005636 (2016).","journal-title":"PLoS Pathog."},{"key":"1372_CR153","doi-asserted-by":"publisher","first-page":"6668","DOI":"10.1021\/jm5007275","volume":"57","author":"MP Clark","year":"2014","unstructured":"Clark, M. P. et al. Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2. J. Med. Chem. 57, 6668\u20136678 (2014).","journal-title":"J. Med. Chem."},{"key":"1372_CR154","doi-asserted-by":"publisher","first-page":"e132","DOI":"10.1093\/infdis\/jiae408","volume":"231","author":"L Leopold","year":"2025","unstructured":"Leopold, L. et al. Efficacy and safety of pimodivir combined with standard of care in hospitalized and nonhospitalized high-risk adolescents and adults with influenza A infection. J. Infect. Dis. 231, e132\u2013e143 (2025).","journal-title":"J. Infect. Dis."},{"key":"1372_CR155","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1128\/AAC.04623-14","volume":"59","author":"RA Byrn","year":"2015","unstructured":"Byrn, R. A. et al. Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit. Antimicrob. Agents Chemother. 59, 1569\u20131582 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1372_CR156","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.antiviral.2012.07.007","volume":"96","author":"F Ferron","year":"2012","unstructured":"Ferron, F., Decroly, E., Selisko, B. & Canard, B. The viral RNA capping machinery as a target for antiviral drugs. Antivir. Res. 96, 21\u201331 (2012).","journal-title":"Antivir. Res."},{"key":"1372_CR157","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nrmicro2675","volume":"10","author":"E Decroly","year":"2012","unstructured":"Decroly, E., Ferron, F., Lescar, J. & Canard, B. Conventional and unconventional mechanisms for capping viral mRNA. Nat. Rev. Microbiol. 10, 51\u201365 (2012).","journal-title":"Nat. Rev. Microbiol."},{"key":"1372_CR158","doi-asserted-by":"publisher","first-page":"7194","DOI":"10.1016\/j.cell.2025.09.022","volume":"188","author":"L Yan","year":"2025","unstructured":"Yan, L. et al. Structural basis for the concurrence of template recycling and RNA capping in SARS-CoV-2. Cell 188, 7194\u20137205.e10 (2025).","journal-title":"Cell"},{"key":"1372_CR159","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-64674-7","volume":"16","author":"M Luo","year":"2025","unstructured":"Luo, M. et al. SARS-CoV-2 NSP14 inhibitor exhibits potent antiviral activity and reverses NSP14-driven host modulation. Nat. Commun. 16, 9671 (2025).","journal-title":"Nat. Commun."},{"key":"1372_CR160","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.str.2025.03.009","volume":"33","author":"A Misra","year":"2025","unstructured":"Misra, A. et al. Structural insights into the assembly and regulation of 2\u2032-O RNA methylation by SARS-CoV-2 nsp16\/nsp10. Structure 33, 1027\u20131039.e4 (2025).","journal-title":"Structure"},{"key":"1372_CR161","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41586-024-08320-0","volume":"637","author":"C Meyer","year":"2025","unstructured":"Meyer, C. et al. Small-molecule inhibition of SARS-CoV-2 NSP14 RNA cap methyltransferase. Nature 637, 1178\u20131185 (2025).","journal-title":"Nature"},{"key":"1372_CR162","doi-asserted-by":"publisher","DOI":"10.1038\/srep31819","volume":"6","author":"L Delang","year":"2016","unstructured":"Delang, L. et al. The viral capping enzyme nsP1: a novel target for the inhibition of chikungunya virus infection. Sci. Rep. 6, 31819 (2016).","journal-title":"Sci. Rep."},{"key":"1372_CR163","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.tim.2025.10.006","volume":"33","author":"P Pushparaj","year":"2025","unstructured":"Pushparaj, P. & Hedestam, G. B. K. On target: antibodies against the neuraminidase active site. Trends Microbiol. 33, 1252\u20131253 (2025).","journal-title":"Trends Microbiol."},{"key":"1372_CR164","doi-asserted-by":"publisher","first-page":"e00040","DOI":"10.1128\/cmr.00040-22","volume":"36","author":"R Kumari","year":"2023","unstructured":"Kumari, R. et al. Antiviral approaches against influenza virus. Clin. Microbiol. Rev. 36, e00040\u201322 (2023).","journal-title":"Clin. Microbiol. Rev."},{"key":"1372_CR165","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s10156-011-0314-2","volume":"18","author":"N Kawai","year":"2012","unstructured":"Kawai, N. et al. Persistence of pandemic influenza H1N1 virus in young patients after oseltamivir therapy in the 2009\u20132010 season: a comparison with seasonal H1N1 with or without H275Y mutation. J. Infect. Chemother. 18, 180\u2013186 (2012).","journal-title":"J. Infect. Chemother."},{"key":"1372_CR166","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1172\/JCI25669","volume":"115","author":"A Moscona","year":"2005","unstructured":"Moscona, A. Entry of parainfluenza virus into cells as a target for interrupting childhood respiratory disease. J. Clin. Invest. 115, 1688\u20131698 (2005).","journal-title":"J. Clin. Invest."},{"key":"1372_CR167","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1021\/acschembio.8b00150","volume":"13","author":"M Pascolutti","year":"2018","unstructured":"Pascolutti, M. et al. Structural insights into human parainfluenza virus 3 hemagglutinin\u2013neuraminidase using unsaturated 3-N-substituted sialic acids as probes. ACS Chem. Biol. 13, 1544\u20131550 (2018).","journal-title":"ACS Chem. Biol."},{"key":"1372_CR168","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/j.jmb.2003.11.032","volume":"335","author":"MC Lawrence","year":"2004","unstructured":"Lawrence, M. C. et al. Structure of the haemagglutinin-neuraminidase from human parainfluenza virus type III. J. Mol. Biol. 335, 1343\u20131357 (2004).","journal-title":"J. Mol. Biol."},{"key":"1372_CR169","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/cwae059","volume":"34","author":"T Takahashi","year":"2024","unstructured":"Takahashi, T. et al. Novel sialidase inhibitors suppress mumps virus replication and infection. Glycobiology 34, cwae059 (2024).","journal-title":"Glycobiology"},{"key":"1372_CR170","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1128\/AAC.48.5.1495-1502.2004","volume":"48","author":"IV Alymova","year":"2004","unstructured":"Alymova, I. V. et al. Efficacy of novel hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 against human parainfluenza viruses in vitro and in vivo. Antimicrob. Agents Chemother. 48, 1495\u20131502 (2004).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1372_CR171","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/nrd1853","volume":"4","author":"AD Kwong","year":"2005","unstructured":"Kwong, A. D., Rao, B. G. & Jeang, K.-T. Viral and cellular RNA helicases as antiviral targets. Nat. Rev. Drug Discov. 4, 845\u2013853 (2005).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1372_CR172","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022336","volume":"6","author":"YA Karpe","year":"2011","unstructured":"Karpe, Y. A., Aher, P. P. & Lole, K. S. NTPase and 5\u2032-RNA triphosphatase activities of chikungunya virus nsP2 protein. PLoS ONE 6, e22336 (2011).","journal-title":"PLoS ONE"},{"key":"1372_CR173","doi-asserted-by":"publisher","first-page":"199401","DOI":"10.1016\/j.virusres.2024.199401","volume":"346","author":"SL Grimes","year":"2024","unstructured":"Grimes, S. L. & Denison, M. R. The coronavirus helicase in replication. Virus Res. 346, 199401 (2024).","journal-title":"Virus Res."},{"key":"1372_CR174","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/nsmb.3258","volume":"23","author":"R Jain","year":"2016","unstructured":"Jain, R., Coloma, J., Garc\u00eda-Sastre, A. & Aggarwal, A. K. Structure of the NS3 helicase from Zika virus. Nat. Struct. Mol. Biol. 23, 752\u2013754 (2016).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"1372_CR175","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abj7615","volume":"8","author":"DL Hurdiss","year":"2022","unstructured":"Hurdiss, D. L. et al. Fluoxetine targets an allosteric site in the enterovirus 2C AAA+ ATPase and stabilizes a ring-shaped hexameric complex. Sci. Adv. 8, eabj7615 (2022).","journal-title":"Sci. Adv."},{"key":"1372_CR176","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01606-17","volume":"92","author":"T-F Li","year":"2018","unstructured":"Li, T.-F. et al. Human norovirus NS3 has RNA helicase and chaperoning activities. J. Virol. 92, e01606-17 (2018).","journal-title":"J. Virol."},{"key":"1372_CR177","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00996-25","volume":"99","author":"T Shu","year":"2025","unstructured":"Shu, T. et al. Respiratory syncytial virus phosphoprotein has NTPase and helicase-like activities. J. Virol. 99, e00996-25 (2025).","journal-title":"J. Virol."},{"key":"1372_CR178","doi-asserted-by":"publisher","first-page":"5837","DOI":"10.1093\/nar\/gkz340","volume":"47","author":"T Shu","year":"2019","unstructured":"Shu, T. et al. Ebola virus VP35 has novel NTPase and helicase-like activities. Nucleic Acids Res. 47, 5837\u20135851 (2019).","journal-title":"Nucleic Acids Res."},{"key":"1372_CR179","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1038\/s41564-025-02168-4","volume":"10","author":"Q Yao","year":"2025","unstructured":"Yao, Q. et al. Structural and mechanistic insights into herpesvirus helicase\u2013primase and its therapeutic inhibitors. Nat. Microbiol. 10, 3191\u20133201 (2025).","journal-title":"Nat. Microbiol."},{"key":"1372_CR180","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-61083-8","volume":"16","author":"K Li","year":"2025","unstructured":"Li, K. et al. A rationally designed 2C inhibitor prevents enterovirus D68-infected mice from developing paralysis. Nat. Commun. 16, 5987 (2025). This study reports the rational design of a 2C helicase inhibitor with in vivo efficacy and broad activity across multiple enteroviruses, validating 2C as a target for pan-enterovirus antiviral development.","journal-title":"Nat. Commun."},{"key":"1372_CR181","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3390\/biom16020273","volume":"16","author":"G Sarvari","year":"2026","unstructured":"Sarvari, G. & Boehr, D. D. Structure, function and inhibition of helicases involved in virus infection. Biomolecules 16, 273 (2026).","journal-title":"Biomolecules"},{"key":"1372_CR182","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1056\/NEJMoa2500179","volume":"393","author":"AP Durbin","year":"2025","unstructured":"Durbin, A. P. et al. Daily mosnodenvir as dengue prophylaxis in a controlled human infection model. N. Engl. J. Med. 393, 2107\u20132118 (2025). This study describes clinical data on mosnodenvir, demonstrating efficacy in a controlled human infection model, further validating NS3\u2013NS4B as a druggable target.","journal-title":"N. Engl. J. Med."},{"key":"1372_CR183","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb2181","volume":"13","author":"SA Moquin","year":"2021","unstructured":"Moquin, S. A. et al. NITD-688, a pan-serotype inhibitor of the dengue virus NS4B protein, shows favorable pharmacokinetics and efficacy in preclinical animal models. Sci. Transl. Med. 13, eabb2181 (2021).","journal-title":"Sci. Transl. Med."},{"key":"1372_CR184","doi-asserted-by":"publisher","first-page":"10774","DOI":"10.1128\/JVI.01253-16","volume":"90","author":"F Guo","year":"2016","unstructured":"Guo, F. et al. A novel benzodiazepine compound inhibits yellow fever virus infection by specifically targeting NS4B protein. J. Virol. 90, 10774\u201310788 (2016).","journal-title":"J. Virol."},{"key":"1372_CR185","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1021\/acsinfecdis.6c00091","volume":"12","author":"S Pang","year":"2026","unstructured":"Pang, S. et al. Drug discovery of antiviral inhibitors targeting dengue virus NS4B protein. ACS Infect. Dis. 12, 1555\u20131571 (2026).","journal-title":"ACS Infect. Dis."},{"key":"1372_CR186","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/s41579-018-0005-4","volume":"16","author":"J Baggen","year":"2018","unstructured":"Baggen, J., Thibaut, H. J., Strating, J. R. P. M. & van Kuppeveld, F. J. M. The life cycle of non-polio enteroviruses and how to target it. Nat. Rev. Microbiol. 16, 368\u2013381 (2018).","journal-title":"Nat. Rev. Microbiol."},{"key":"1372_CR187","doi-asserted-by":"publisher","first-page":"10768","DOI":"10.1128\/JVI.00941-08","volume":"82","author":"RA Larson","year":"2008","unstructured":"Larson, R. A. et al. Identification of a broad-spectrum arenavirus entry inhibitor. J. Virol. 82, 10768\u201310775 (2008).","journal-title":"J. Virol."},{"key":"1372_CR188","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/j.chom.2025.07.020","volume":"33","author":"M Katz","year":"2025","unstructured":"Katz, M. et al. pH-induced conformational changes and inhibition of the Lassa virus spike complex. Cell Host Microbe 33, 1577\u20131588.e7 (2025).","journal-title":"Cell Host Microbe"},{"key":"1372_CR189","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3390\/v12030342","volume":"12","author":"M Aggarwal","year":"2020","unstructured":"Aggarwal, M. & Plemper, R. K. Structural insight into paramyxovirus and pneumovirus entry inhibition. Viruses 12, 342 (2020).","journal-title":"Viruses"},{"key":"1372_CR190","doi-asserted-by":"publisher","first-page":"18491","DOI":"10.1021\/acs.jmedchem.5c01357","volume":"68","author":"S Rimaux","year":"2025","unstructured":"Rimaux, S. et al. N-[(Thiophen-3-yl)methyl]benzamides as fusion inhibitors of influenza virus targeting H1 and H5 hemagglutinins. J. Med. Chem. 68, 18491\u201318518 (2025).","journal-title":"J. Med. Chem."},{"key":"1372_CR191","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3390\/ph14060587","volume":"14","author":"Z Chen","year":"2021","unstructured":"Chen, Z., Cui, Q., Caffrey, M., Rong, L. & Du, R. Small molecule inhibitors of influenza virus entry. Pharmaceuticals 14, 587 (2021).","journal-title":"Pharmaceuticals"},{"key":"1372_CR192","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ady3554","volume":"11","author":"S Ezzatpour","year":"2025","unstructured":"Ezzatpour, S. et al. Broad-spectrum synthetic carbohydrate receptors (SCRs) inhibit viral entry across multiple virus families. Sci. Adv. 11, eady3554 (2025).","journal-title":"Sci. Adv."},{"key":"1372_CR193","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adv9311","volume":"11","author":"G Mathez","year":"2025","unstructured":"Mathez, G. et al. A pan-respiratory virus attachment inhibitor with high potency in human airway models and in vivo. Sci. Adv. 11, eadv9311 (2025).","journal-title":"Sci. Adv."},{"key":"1372_CR194","doi-asserted-by":"publisher","first-page":"21072","DOI":"10.1021\/acs.jmedchem.5c01625","volume":"68","author":"E Canales","year":"2025","unstructured":"Canales, E. et al. Discovery of lenacapavir: first-in-class twice-yearly capsid inhibitor for HIV-1 treatment and pre-exposure prophylaxis. J. Med. Chem. 68, 21072\u201321094 (2025).","journal-title":"J. Med. Chem."},{"key":"1372_CR195","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s41586-025-08651-6","volume":"640","author":"E Van Damme","year":"2025","unstructured":"Van Damme, E. et al. A small-molecule SARS-CoV-2 inhibitor targeting the membrane protein. Nature 640, 506\u2013513 (2025).","journal-title":"Nature"},{"key":"1372_CR196","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abn1440","volume":"8","author":"MJ Norris","year":"2022","unstructured":"Norris, M. J. et al. Measles and Nipah virus assembly: specific lipid binding drives matrix polymerization. Sci. Adv. 8, eabn1440 (2022).","journal-title":"Sci. Adv."},{"key":"1372_CR197","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/17425255.2020.1711884","volume":"16","author":"M Miao","year":"2020","unstructured":"Miao, M., De Clercq, E. & Li, G. Clinical significance of chemokine receptor antagonists. Expert Opin. Drug Metab. Toxicol. 16, 11\u201330 (2020).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"1372_CR198","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41575-022-00608-8","volume":"19","author":"MP Manns","year":"2022","unstructured":"Manns, M. P. & Maasoumy, B. Breakthroughs in hepatitis C research: from discovery to cure. Nat. Rev. Gastroenterol. Hepatol. 19, 533\u2013550 (2022).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1372_CR199","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3897\/pharmacia.72.e159854","volume":"72","author":"F Orosco","year":"2025","unstructured":"Orosco, F. Pan-viral efficacy profile of ribavirin: quantitative potency and safety landscape across virus families. Pharmacia 72, 1\u201311 (2025).","journal-title":"Pharmacia"},{"key":"1372_CR200","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.coviro.2014.04.011","volume":"8","author":"S Beaucourt","year":"2014","unstructured":"Beaucourt, S. & Vignuzzi, M. Ribavirin: a drug active against many viruses with multiple effects on virus replication and propagation. Molecular basis of ribavirin resistance. Curr. Opin. Virol. 8, 10\u201315 (2014).","journal-title":"Curr. Opin. Virol."},{"key":"1372_CR201","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1128\/JVI.79.3.1943-1947.2005","volume":"79","author":"P Leyssen","year":"2005","unstructured":"Leyssen, P., Balzarini, J., De Clercq, E. & Neyts, J. The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J. Virol. 79, 1943\u20131947 (2005).","journal-title":"J. Virol."},{"key":"1372_CR202","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1136\/gutjnl-2012-303852","volume":"63","author":"Y Rotman","year":"2014","unstructured":"Rotman, Y. et al. Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. Gut 63, 161\u2013169 (2014).","journal-title":"Gut"},{"key":"1372_CR203","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/rmv.483","volume":"16","author":"JD Graci","year":"2006","unstructured":"Graci, J. D. & Cameron, C. E. Mechanisms of action of ribavirin against distinct viruses. Rev. Med. Virol. 16, 37\u201348 (2006).","journal-title":"Rev. Med. Virol."},{"key":"1372_CR204","volume":"6","author":"S Johnson","year":"2018","unstructured":"Johnson, S. et al. Ribavirin for treating Crimean Congo haemorrhagic fever. Cochrane Database Syst. Rev. 6, CD012713 (2018).","journal-title":"Cochrane Database Syst. Rev."},{"key":"1372_CR205","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2421573122","volume":"122","author":"W Qiao","year":"2025","unstructured":"Qiao, W., Xie, X., Shi, P.-Y., Ooi, Y. S. & Carette, J. E. Druggable genome screens identify SPP as an antiviral host target for multiple flaviviruses. Proc. Natl Acad. Sci. USA 122, e2421573122 (2025).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1372_CR206","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1107\/S2053230X18010415","volume":"74","author":"M Dujardin","year":"2018","unstructured":"Dujardin, M., Bouckaert, J., Rucktooa, P. & Hanoulle, X. X-ray structure of alisporivir in complex with cyclophilin A at 1.5 \u00c5 resolution. Acta Crystallogr. F 74, 583\u2013592 (2018).","journal-title":"Acta Crystallogr. F"},{"key":"1372_CR207","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013687","volume":"5","author":"L Coelmont","year":"2010","unstructured":"Coelmont, L. et al. DEB025 (alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin a induced cis-trans isomerisation in domain II of NS5A. PLoS ONE 5, e13687 (2010).","journal-title":"PLoS ONE"},{"key":"1372_CR208","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1080\/14656566.2018.1560424","volume":"20","author":"C Stanciu","year":"2019","unstructured":"Stanciu, C., Trifan, A., Muzica, C. & Sfarti, C. Efficacy and safety of alisporivir for the treatment of hepatitis C infection. Expert Opin. Pharmacother. 20, 379\u2013384 (2019).","journal-title":"Expert Opin. Pharmacother."},{"key":"1372_CR209","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2024.106003","volume":"231","author":"MG Martina","year":"2024","unstructured":"Martina, M. G. et al. Bithiazole inhibitors of PI4KB show broad-spectrum antiviral activity against different viral families. Antivir. Res. 231, 106003 (2024).","journal-title":"Antivir. Res."},{"key":"1372_CR210","first-page":"3375","volume":"73","author":"L Delang","year":"2018","unstructured":"Delang, L. et al. PI4KIII inhibitor enviroxime impedes the replication of the hepatitis C\u00a0virus by inhibiting PI3 kinases. J. Antimicrob. Chemother. 73, 3375\u20133384 (2018).","journal-title":"J. Antimicrob. Chemother."},{"key":"1372_CR211","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.31195","volume":"239","author":"H Zhao","year":"2024","unstructured":"Zhao, H. et al. Locational and functional characterization of PI4KB in the mouse embryo. J. Cell. Physiol. 239, e31195 (2024).","journal-title":"J. Cell. Physiol."},{"key":"1372_CR212","doi-asserted-by":"publisher","first-page":"3358","DOI":"10.1128\/AAC.00303-13","volume":"57","author":"C Spickler","year":"2013","unstructured":"Spickler, C. et al. Phosphatidylinositol 4-kinase III beta is essential for replication of human rhinovirus and its inhibition causes a lethal phenotype in vivo. Antimicrob. Agents Chemother. 57, 3358\u20133368 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1372_CR213","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/S0140-6736(81)92520-4","volume":"317","author":"R Phillpotts","year":"1981","unstructured":"Phillpotts, R. et al. The activity of enviroxime against rhinovirus infection in man. Lancet 317, 1342\u20131344 (1981).","journal-title":"Lancet"},{"key":"1372_CR214","doi-asserted-by":"publisher","first-page":"4529","DOI":"10.3390\/v7082832","volume":"7","author":"L van der Linden","year":"2015","unstructured":"van der Linden, L., Wolthers, K. C. & van Kuppeveld, F. J. Replication and inhibitors of enteroviruses and parechoviruses. Viruses 7, 4529\u20134562 (2015).","journal-title":"Viruses"},{"key":"1372_CR215","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","volume":"21","author":"M B\u00e9k\u00e9s","year":"2022","unstructured":"B\u00e9k\u00e9s, M., Langley, D. R. & Crews, C. M. PROTAC targeted protein degraders: the past is prologue. Nat. Rev. Drug Discov. 21, 181\u2013200 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1372_CR216","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.bbrc.2014.10.006","volume":"453","author":"K Montrose","year":"2014","unstructured":"Montrose, K. & Krissansen, G. W. Design of a PROTAC that antagonizes and destroys the cancer-forming X-protein of the hepatitis B virus. Biochem. Biophys. Res. Commun. 453, 735\u2013740 (2014).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1372_CR217","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11429-w","volume":"10","author":"M de Wispelaere","year":"2019","unstructured":"de Wispelaere, M. et al. Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations. Nat. Commun. 10, 3468 (2019).","journal-title":"Nat. Commun."},{"key":"1372_CR218","doi-asserted-by":"publisher","first-page":"6495","DOI":"10.1021\/acs.jmedchem.3c02416","volume":"67","author":"YR Alugubelli","year":"2024","unstructured":"Alugubelli, Y. R. et al. Discovery of first-in-class PROTAC degraders of SARS-CoV-2 main protease. J. Med. Chem. 67, 6495\u20136507 (2024).","journal-title":"J. Med. Chem."},{"key":"1372_CR219","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.chom.2023.05.030","volume":"31","author":"N Zhao","year":"2023","unstructured":"Zhao, N. et al. Generation of host-directed and virus-specific antivirals using targeted protein degradation promoted by small molecules and viral RNA mimics. Cell Host Microbe 31, 1154\u20131169.e10 (2023).","journal-title":"Cell Host Microbe"},{"key":"1372_CR220","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56317-8","volume":"16","author":"LS Newton","year":"2025","unstructured":"Newton, L. S. et al. Macrocycle-based PROTACs selectively degrade cyclophilin A and inhibit HIV-1 and HCV. Nat. Commun. 16, 1484 (2025).","journal-title":"Nat. Commun."},{"key":"1372_CR221","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.3390\/molecules30163402","volume":"30","author":"J Jin","year":"2025","unstructured":"Jin, J. et al. PROTACs in antivirals: current advancements and future perspectives. Molecules 30, 3402 (2025).","journal-title":"Molecules"},{"key":"1372_CR222","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1080\/17568919.2025.2453418","volume":"17","author":"RP Bhole","year":"2025","unstructured":"Bhole, R. P., Kute, P. & Gurav, S. S. PROTACs in the treatment of viral diseases. Future Med. Chem. 17, 267\u2013269 (2025).","journal-title":"Future Med. Chem."},{"key":"1372_CR223","doi-asserted-by":"publisher","first-page":"819165","DOI":"10.3389\/fchem.2021.819165","volume":"9","author":"Z Lv","year":"2022","unstructured":"Lv, Z. et al. Targeting SARS-CoV-2 proteases for COVID-19 antiviral development. Front. Chem. 9, 819165 (2022).","journal-title":"Front. Chem."},{"key":"1372_CR224","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nrd2400","volume":"6","author":"M von Itzstein","year":"2007","unstructured":"von Itzstein, M. The war against influenza: discovery and development of sialidase inhibitors. Nat. Rev. Drug Discov. 6, 967\u2013974 (2007).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1372_CR225","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/med.22080","volume":"45","author":"K Zhang","year":"2025","unstructured":"Zhang, K. et al. Deciphering the enigmas of non-nucleoside reverse transcriptase inhibitors (NNRTIs): a medicinal chemistry expedition towards combating HIV drug resistance. Med. Res. Rev. 45, 426\u2013483 (2025).","journal-title":"Med. Res. Rev."},{"key":"1372_CR226","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3000281","volume":"17","author":"R Abdelnabi","year":"2019","unstructured":"Abdelnabi, R. et al. A novel druggable interprotomer pocket in the capsid of rhino- and enteroviruses. PLoS Biol. 17, e3000281 (2019).","journal-title":"PLoS Biol."},{"key":"1372_CR227","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41573-020-00117-w","volume":"20","author":"SN Chandrasekaran","year":"2021","unstructured":"Chandrasekaran, S. N., Ceulemans, H., Boyd, J. D. & Carpenter, A. E. Image-based profiling for drug discovery: due for a machine-learning upgrade? Nat. Rev. Drug Discov. 20, 145\u2013159 (2021). This review provides an overview on image-based profiling to capture rich, multi-dimensional biological information from biological images and discusses how machine-learning approaches can accelerate drug discovery.","journal-title":"Nat. Rev. Drug Discov."},{"key":"1372_CR228","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s44320-026-00197-7","volume":"22","author":"E Serrano","year":"2026","unstructured":"Serrano, E. et al. Progress and new challenges in image-based profiling. Mol. Syst. Biol. 22, 624\u2013658 (2026).","journal-title":"Mol. Syst. Biol."},{"key":"1372_CR229","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1038\/nprot.2016.105","volume":"11","author":"M-A Bray","year":"2016","unstructured":"Bray, M.-A. et al. Cell Painting, a high-content image-based assay for morphological profiling using multiplexed fluorescent dyes. Nat. Protoc. 11, 1757\u20131774 (2016).","journal-title":"Nat. Protoc."},{"key":"1372_CR230","doi-asserted-by":"publisher","DOI":"10.1186\/s12915-021-01086-1","volume":"19","author":"J Rietdijk","year":"2021","unstructured":"Rietdijk, J. et al. A phenomics approach for antiviral drug discovery. BMC Biol. 19, 156 (2021).","journal-title":"BMC Biol."},{"key":"1372_CR231","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49444-1","volume":"15","author":"A Petkidis","year":"2024","unstructured":"Petkidis, A., Andriasyan, V., Murer, L., Volle, R. & Greber, U. F. A versatile automated pipeline for quantifying virus infectivity by label-free light microscopy and artificial intelligence. Nat. Commun. 15, 5112 (2024).","journal-title":"Nat. Commun."},{"key":"1372_CR232","doi-asserted-by":"publisher","first-page":"002067","DOI":"10.1099\/jgv.0.002067","volume":"106","author":"S Bowyer","year":"2025","unstructured":"Bowyer, S., Allen, D. J. & Furnham, N. Unveiling the ghost: machine learning\u2019s impact on the landscape of virology. J. Gen. Virol. 106, 002067 (2025).","journal-title":"J. Gen. Virol."},{"key":"1372_CR233","doi-asserted-by":"publisher","DOI":"10.1126\/science.ads9530","volume":"391","author":"Y Jia","year":"2026","unstructured":"Jia, Y. et al. Deep contrastive learning enables genome-wide virtual screening. Science 391, eads9530 (2026). This paper describes DrugCLIP, a virtual genome-wide screening drug discovery tool.","journal-title":"Science"},{"key":"1372_CR234","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1007\/s11095-017-2192-5","volume":"34","author":"RLA de Vrueh","year":"2017","unstructured":"de Vrueh, R. L. A. & Crommelin, D. J. A. Reflections on the future of pharmaceutical public-private partnerships: from input to impact. Pharm. Res. 34, 1985\u20131999 (2017).","journal-title":"Pharm. Res."},{"key":"1372_CR235","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3389\/fmed.2019.00114","volume":"6","author":"RLA de Vrueh","year":"2019","unstructured":"de Vrueh, R. L. A., de Vlieger, J. S. B. & Crommelin, D. J. A. Editorial: public-private partnerships as drivers of innovation in healthcare. Front. Med. 6, 114 (2019).","journal-title":"Front. Med."},{"key":"1372_CR236","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration. Product Development Under the Animal Rule https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/product-development-under-animal-rule (FDA, 2015)."},{"key":"1372_CR237","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1016\/j.tibtech.2025.12.011","volume":"44","author":"S Gerke","year":"2026","unstructured":"Gerke, S., Balamut, J. & Wagner, J. K. The FDA\u2019s plan to phase out animal testing. Trends Biotechnol. 44, 2178\u20132181 (2026).","journal-title":"Trends Biotechnol."},{"key":"1372_CR238","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.antiviral.2019.06.005","volume":"168","author":"M Merchlinsky","year":"2019","unstructured":"Merchlinsky, M. et al. The development and approval of tecoviromat (TPOXX\u00ae), the first antiviral against smallpox. Antivir. Res. 168, 168\u2013174 (2019).","journal-title":"Antivir. Res."},{"key":"1372_CR239","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1056\/NEJMoa2412439","volume":"392","author":"R Ali","year":"2025","unstructured":"Ali, R. et al. Tecovirimat for clade I MPXV infection in the Democratic Republic of Congo. N. Engl. J. Med. 392, 1484\u20131496 (2025). This study describes the limited efficacy of tecovirimat, an antiviral drug approved under the Animal Rule.","journal-title":"N. Engl. J. Med."},{"key":"1372_CR240","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2024.101745","volume":"85","author":"M Cavaleri","year":"2024","unstructured":"Cavaleri, M. et al. Fourth controlled human infection model (CHIM) meeting, CHIM regulatory issues, May 24, 2023. Biologicals 85, 101745 (2024).","journal-title":"Biologicals"},{"key":"1372_CR241","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.3390\/v14071427","volume":"14","author":"M Hites","year":"2022","unstructured":"Hites, M. & Vincent, J.-L. Pharmacological studies in hospitalized COVID-19 patients in Belgium: we could do better. Viruses 14, 1427 (2022).","journal-title":"Viruses"},{"key":"1372_CR242","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1016\/S1473-3099(21)00705-2","volume":"22","author":"H Goossens","year":"2022","unstructured":"Goossens, H., Derde, L., Horby, P. & Bonten, M. The European clinical research response to optimise treatment of patients with COVID-19: lessons learned, future perspective, and recommendations. Lancet Infect. Dis. 22, e153\u2013e158 (2022). This paper provides an overview on lessons learned from the SARS-CoV-2 pandemic and recommends improvements to our response to future outbreaks.","journal-title":"Lancet Infect. Dis."},{"key":"1372_CR243","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41573-019-0034-3","volume":"18","author":"DC Angus","year":"2019","unstructured":"Angus, D. C. et al. Adaptive platform trials: definition, design, conduct and reporting considerations. Nat. Rev. Drug Discov. 18, 797\u2013807 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1372_CR244","doi-asserted-by":"publisher","first-page":"150935","DOI":"10.1016\/j.tmrv.2025.150935","volume":"39","author":"NA Angeloni","year":"2025","unstructured":"Angeloni, N. A., Adhikari, N. K. & Lamontagne, F. A practical review of adaptive platform trials. Transfus. Med. Rev. 39, 150935 (2025).","journal-title":"Transfus. Med. Rev."},{"key":"1372_CR245","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/d41586-026-01607-4","volume":"653","author":"E Callaway","year":"2026","unstructured":"Callaway, E. Race begins to trial Ebola drugs amid current outbreak. Nature 653, 987\u2013988 (2026).","journal-title":"Nature"},{"key":"1372_CR246","unstructured":"World Health Organization. Integrating Research into Outbreaks: How Can We Prepare for the Next Marburg Outbreak? https:\/\/www.who.int\/news-room\/events\/detail\/2023\/03\/10\/default-calendar\/who-consultation---integrating-research-into-outbreaks--how-can-we-prepare-for-the-next-marburg-outbreak (WHO, 2023)."},{"key":"1372_CR247","doi-asserted-by":"publisher","first-page":"e253","DOI":"10.1016\/S1473-3099(22)00810-6","volume":"23","author":"E Torreele","year":"2023","unstructured":"Torreele, E. et al. Breakthrough treatments for Ebola virus disease, but no access\u2014what went wrong, and how can we do better? Lancet Infect. Dis. 23, e253\u2013e258 (2023). This paper describes why effective Ebola treatments, diagnostics and vaccines remain largely inaccessible in affected regions and describes the framework required to make these countermeasures become available where and when they are most needed.","journal-title":"Lancet Infect. Dis."}],"container-title":["Nature Reviews Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41579-026-01372-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41579-026-01372-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41579-026-01372-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:03:37Z","timestamp":1791414217000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41579-026-01372-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":247,"alternative-id":["1372"],"URL":"https:\/\/doi.org\/10.1038\/s41579-026-01372-1","relation":{},"ISSN":["1740-1526","1740-1534"],"issn-type":[{"value":"1740-1526","type":"print"},{"value":"1740-1534","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"assertion":[{"value":"9 September 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.J.T., D.J., M.L. and J.N. are inventors on patents relating to small molecule antivirals for (i) orthoflaviviruses, RSV, enteroviruses and coronaviruses (J.N.), (ii) enteroviruses (H.J.T.), (iii) RSV and coronaviruses (D.J.) or (iv) coronaviruses (M.L.). L.L. has received consultancy fees from Siga Technologies, Emergent BioSolutions and BioNTech.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}